Hematopoietic Stem Cells Transplantation (HSCT) Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, UK, Germany, Canada, China - Size and Forecast 2024-2028

Hematopoietic Stem Cells Transplantation Market Size 2024-2028

The global hematopoietic stem cells transplantation (HSCT) market size is estimated to grow by USD 2.58 billion at a CAGR of 6.64% between 2023 and 2028. Factors influencing market growth include the advancement of technology, rising demand for customized medicine, and decreased morbidity and mortality rates. The improved treatment options, HLA typing, and supportive care given to patients prior to or after the transplant help them fight infectious diseases and that is why hematopoietic stem cell transplantation has become a preferable option. Owing to the increasing emergence of regenerative therapies across the world, this market will significantly grow during the forecast period. It is an oligopoly market that is mainly dominated by key vendors such as AllCells, Lonza, Merck, and Sanofi, followed by other prominent vendors such as STEMCELL Technologies and Mesoblast. The market is witnessing strong research and development in the field of stem cells, which is expected to help some new companies enter the market.  It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2018 - 2022, besides analyzing the current market scenario.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, Download Report Sample

Market Segmentation by Application, Type, and Geography

The market plays a crucial role in treating various hematological disorders such as leukemia and lymphoma, which are significant health concerns globally. Organizations like the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) provide guidelines and support for managing these conditions. Autologous transplantation and allogeneic transplantation, including bone marrow transplant and cord blood transplant, are common procedures in this market. Healthcare providers like the Leukemia & Lymphoma Society (LLS) contribute significantly to research, clinical trials, and therapies for lymphoproliferative disorders. The rising prevalence of cancer and its status as a leading cause of death emphasizes the importance of advancements in stem cell transplants and therapeutic cells, driving inorganic growth strategies and addressing the public health emergency posed by these conditions.

Application Analysis

The bone marrow transplant segment is estimated to witness significant growth during the forecast period.  A bone marrow transplant is a treatment that replaces bone marrow that is not producing enough healthy blood cells or is dysfunctional with healthy blood-forming stem cells. Doctors and medical practitioners recommend bone marrow transplants to patients suffering from several malignant and noncancerous disorders, including acute leukemia, adrenoleukodystrophy, chronic leukemia, aplastic anemia, bone marrow failure syndromes, and others.

Get a glance at the market contribution of various segments Download PDF Sample

The bone marrow transplant segment was valued at USD 2.75 billion in 2018 and continued to grow during the forecast period. Bone marrow transplant also improves the prospects of cure and survival for patients with such disorders, resulting in a rising demand for bone marrow transplants among patients. This, in turn, will fuel the global hematopoietic stem cell transplantation (HSCT) market's growth throughout the forecast period.

Type Analysis

The type segment is divided into two parts: autologous HSCT and allogeneic HSCT. The major advantage of an autologous transplant is the body recognizes its cells, and hence, does not reject the transplant. This also indicates lesser chances of GvHD. The autologous HSCT segment of the global market currently dominates the global market, with the highest market share of 59.00% in 2021. Moreover, autologous transplant involves cryopreservation of the stem cells, which allows the administration of high doses of chemotherapy and radiotherapy to be risk-free. Further, an autologous transplant ensures rapid immune recovery of the patients, which would ultimately drive market growth during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers will shape the market during the forecast period. In 2022, the US was the largest revenue contributor to the HSCT market in the region, attributed to the increasing awareness about stem cell therapy in the country and the availability of advanced healthcare infrastructure. This ensures the continuous delivery of therapies to patients undergoing treatment. Hence, the market in the US is expected to grow steadily during the forecast period.

Unlike the traditional therapeutic market, there are a number of policies and regulation-related considerations pertaining to the use of stem cell therapies. However, despite stringent regulations laid by regulatory authorities in the region, many factors, such as the high prevalence of bone marrow diseases and several types of blood carcinomas, are propelling the market growth in North America. Furthermore, healthcare is financed through a mix of financing arrangements, including government spending and compulsory health insurance, as well as voluntary health insurance and private funds such as households' out-of-pocket payments, NGOs, and private corporations (together termed as voluntary). All these factors are expected to drive the growth of the market in the US and, subsequently, in North America during the forecast period.

Buy Full Report Now

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

AllCells Corp- To make an impact in the hematopoietic stem cells industry, the company provides a wide range of human hematopoietic cells and molecular products such as whole blood, leukoplakia, mobilized leukoplakia, bone marrow, and cord blood.

Athersys Inc., Beike Biotechnology Co. Ltd., bluebird bio Inc., Cellular Biomedicine Group Inc., FUJIFILM Corp., Gamida Cell Ltd., Lineage Cell Therapeutics Inc., Lonza Group Ltd., MEDIPOST Co. Ltd., Merck and Co. Inc., Mesoblast Ltd., Pluristem Therapeutics Inc., Sanofi SA, Sartorius CellGenix GmbH, Taiga Biotechnologies Inc., Takeda Pharmaceutical Co. Ltd., Talaris Therapeutics Inc., and ThermoGenesis Holdings Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics and Customer Landscape

The market is driven by factors such as increasing cases of leukemia and lymphoma, prompting organizations like the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) to emphasize research and treatment protocols. Advancements in autologous transplantation and allogeneic transplantation, along with innovative therapies from companies like Magenta Biosciences and Gamida Cell, are key trends. However, challenges like high healthcare expenditure, managing graft-versus-host disease (GVHD), and addressing the public health emergency of hematological disorders remain significant hurdles in the HSCT market. There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. 

Key Market Driver

Recent years have witnessed a rise in the adoption of hematopoietic stem cells transplantation (HSCT) due to the development of safer procedures and improved success rates resulting from technological advancements. This trend is expected to continue during the forecast period, with the global HSCT market being driven by advancements in technology, particularly the development of better and more sophisticated instruments. For example, Ranfac has introduced its patented technology, Marrow Cellution, to address the challenges associated with conventional transplant syringes.

Moreover, the use of traditional needles has often led to contamination of peripheral blood, resulting in poor cellular yield. This has necessitated the adoption of measures to meet the desired cellular demands for treating various diseases. Therefore, the Marrow Cellution technology, which enables high-quality stem and progenitor cells to be harvested within a narrow space with limited peripheral blood contamination, is expected to fuel the market growth during the forecast period

Significant Market Trend

Growing demand for personalized medicine is a notable trend in the market. The concept of personalized medicine involves tailoring treatments to the specific needs, characteristics, and preferences of individual patients. To this end, research organizations are exploring various ways to develop personalized treatments using mesenchymal stem cells due to their numerous benefits. These benefits include a lower risk of immune rejection, no need for embryonic stem cells, reduced dependence on anti-rejection drugs, lower risk of graft rejection, and a decreased chance of developing GvHD.

While immunosuppressive therapy is the mainstay of treatment for hematological malignancies and solid tumors, its side effects often outweigh its therapeutic benefits. Mesenchymal stem cells (MSC), which are located in the vascular region of the bone marrow, provide cellular support to the HSC niche and possess immunosuppressive properties that are beneficial for HSCT and the treatment of inflammatory and autoimmune diseases. As a result, the use of MSC during HSCT has led to improved engraftment rates of hematopoietic stem cells by reducing the incidence of GvHD, which is expected to contribute to market growth during the forecast period.

Major Market Challenge

Increased risk of complications post-HSCT is a major challenge in the market. The field of transplant technology and supportive care practices has seen significant advancements, resulting in improved survival rates among patients following transplantation. However, despite these developments, individuals who have undergone hematopoietic stem cell transplantation (HSCT) remain at risk of developing long-term complications, including endocrinopathy, cardiopulmonary issues, musculoskeletal disorders, and subsequent malignancies.

Moreover, these complications have a direct impact on the mortality and morbidity rates of HSCT patients. As a result, the increased morbidity experienced by HSCT patients has led to a growing demand for alternative treatment regimens, which is hindering market growth during the forecast period.

Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

 Customer Landscape

Segment Overview

The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.

• Type Outlook 
  • Autologous HSCT
  • Allogeneic HSCT

• Application Outlook
  • Bone marrow transplant
  • Peripheral blood stem cell transplant
  • Cord blood transplant

• Region Outlook 
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World
    • Australia
    • Argentina
    • Brazil

You may also interested in below market reports:

• Stem Cell Banking Market: Stem Cell Banking Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast
• Stem Cell Therapy Market: Stem Cell Therapy Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Japan - Size and Forecast
• Apheresis Devices Market: Apheresis Devices Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast

Market Analyst Overview

The market is a critical aspect of modern healthcare, addressing complex conditions like lymphoma, leukemia, and graft-versus-host disease (GVHD). Organizations like the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) play pivotal roles in research and advocacy. Companies such as Magenta Biosciences and Priothera are driving innovations in stem cell-based medicines and immune cloaking technologies. The market witnesses substantial investments in therapeutic and diagnostic devices for transplantation procedures like autologous and allogeneic transplantation. However, challenges like reduction in bed capacity and healthcare expenditure persist, emphasizing the need for continual advancements and collaborations in this critical area of healthcare.

Moreover, the market is a vital component of the healthcare industry, particularly in addressing complex conditions such as leukemia, lymphoma, and hematological disorders. Organizations like the World Cancer Research Fund and the Leukemia & Lymphoma Society (LLS) play crucial roles in funding research and supporting patients diagnosed with common cancers. Clinical trials and innovative treatments like autologous and allogeneic transplant therapy for bone marrow stem cell transplant are conducted at renowned centers like QUINT Bone Marrow Transplant Center. Companies like Clade Therapeutics focus on induced pluripotent stem cells (iPSCs) and therapeutic cells for effective treatment. However, challenges such as reduction in bed capacity and demand for drugs highlight the need for continuous advancements and collaborations in this field. The American College of Surgeons (ACS) guides surgical interventions, including bone marrow transplant (BMT), peripheral blood stem cells transplant (PBSCT), and cord blood transplant (CBT), further underlining the significance of HSCT in combating life-threatening conditions.

Furthermore, the market is a critical aspect of healthcare, particularly in addressing hematological disorders like acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), Hodgkin lymphoma (HL), Non-Hodgkin lymphoma (NHL), and multiple myeloma (MM). Autologous transplantation and stem cell transplants are key therapies for these conditions, helping combat lymphoproliferative disorders and reduce the prevalence of cancer, which is a leading cause of death worldwide. The market landscape depends on haematological disorders and autologous transplant therapy. However, challenges such as acute graft-versus-host disease (GVHD), reduction in bed and operating room capacity, and production and demand of drugs present obstacles in effectively managing these diseases. Strategic initiatives like inorganic growth strategies are being employed to address the public health emergency posed by these disorders and ensure access to life-saving treatments for patients.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the between 2024 and 2028
• Precise estimation of the size and its contribution n of the market in focus to the parent market
• Detailed market growth and forecasting analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market industry across North America, Europe, Asia, and Rest of World (ROW)
• Thorough Market forecasting analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive market forecast analysis of factors that will challenge the growth of companies